MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study

Merck (MRK) announced data from the phase III KEYFORM-007 study, which evaluated a fixed-dose combination of its anti-LAG-3 antibody, favezelimab and its blockbuster anti-PD-1 therapy, Keytruda in pre-treated patients with PD-L1 positive microsatellite stable (MSS) metastatic colorectal cancer (mCRC).The study failed to meet the primary endpoint of overall survival (OS).Year to date, shares of Merck have gained 5.2% compared with the industry’s rise of 22.8%.Image Source: Zacks Investment ResearchWhat Did M ...